" class="no-js "lang="en-US"> DiamiR Biosciences - Medtech Alert
Sunday, September 14, 2025
DiamiR Biosciences | Pharmtech Focus

DiamiR Biosciences

About DiamiR Biosciences

DiamiR Biosciences

DiamiR is a privately held molecular diagnostics company focused on developing minimally invasive tests for detection and monitoring of pathology based on quantitative analysis of organ-enriched microRNA signatures in plasma for screening, patient stratification, as well as disease progression and treatment monitoring. DiamiR collaborates with leading academic centers, disease foundations, and biopharma companies.

Related Story

DiamiR Biosciences Expands Management Team with the Appointment of Fred Knechtel as its Chief Financial Officer

August 31 2022

DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today […]